Skip to main content
. 2012 Jan;15(1):118–127. doi: 10.1016/j.jval.2011.08.002

Table 3.

Utility, visual acuity (VA) and visual analogue scale (VAS) values.

Study reference (author, year) Instrument Index (mean (SD)) VA (logMAR mean (SD) unless specified) VAS (mean (SD))
Glaucoma
 Aspinall et al. 2008 [10] EQ-5D 0.76 (0.19) Median group 6/12 or better in both eyes
 Kobelt et al. 2006 [11] EQ-5D 0.80 (0.23) (right/left) 0.76/0.74 (0.30/0.29) 74.7 (18.2)
 Mittmann et al. 2001 [12] HUI-3 0.924 (0.086)
 Montemayor et al. 2001 [13] EQ-5D 0.89 (range −0.08 to 1.00) −0.10 (0.17)
 Thygesen et al. 2008 [14] EQ-5D 0.65 (0.28) Best/worst eye 0.28(0.26) / 0.14(0.18)
Age-related macular degeneration
 Cruess et al. 2007 [15] EQ-5D 0.64 (0.52,0.76) 0.66 (0.64)
 Espallargues et al. 2005 [16] EQ-5D 0.72 (0.22)

  • Better seeing eye 1.01 (0.67)

  • Worse seeing eye 1.68 (0.75)

 65.0
SF-6D 0.66 (0.14)
HUI-3 0.34 (0.28)
 Kim et al. 2010 [17] EQ-5D Pre-treatment 0.729 (0.236) Post-treatment 0.793 (0.222)
 Lotery et al. 2007 [18] EQ-5D 0.67 0.26 (0.19)
 Payakachat et al. 2009 [19] EQ-5D 0.7711 (0.21) Median group for Better and worse eye groups: 20/80 to 20/160
 Ruiz-Moreno et al. 2008 [20] EQ-5D 0.68 (0.62,0.74) 95% CI
 Soubrane et al. 2007 [21] EQ-5D 0.65 0.6 (0.7)
Cataracts
 Asakawa et al. 2008 [22] HUI-3 -
 Black et al. 2009 [23] EQ-5D 0.81 (0.23)
 Conner-Spady et al. 2005 [24] EQ-5D

  • First eye surgery 0.80 (0.20)

  • Second eye surgery 0.78 (0.20)

 First eye, second eye VA op 0.58 (0.30), 0.52 (0.27) VA non-op 0.43 (0.28), 0.29 (0.21)

  • First eye surgery 77.5 (17.9)

  • Second eye surgery 77.1 (16.6)
 Datta et al. 2008 [25] EQ-5D Median 0.73 (0.26) 0.28 [0.16;0.42]
 Jayamanne et al. 1999 [26] EQ-5D - 90% had VA 6/18-6/60
 Polack et al. 2007 [27] EQ-5D - Median group < 6/60 > 3/60
 Polack et al. 2008 [28] EQ-5D - Median group < 3/60 > PL
 Polack et al. 2010 [29] EQ-5D - Median group < 3/60 > PL
Diabetic retinopathy
 Lloyd et al. 2008 (30) EQ-5D, HUI-3

  • By level of VA:

  • No DR - 0.83 (0.20), 0.81 (0.20)

  • 6/6-6/9 - 0.83 (0.20), 0.78 (0.22)

  • 6/12-6/18 - 0.50 (0.30), 0.30 (0.38)

  • 6/24-6/36 - 0.68 (0.29), 0.61 (0.35)

  • 6/60-6/120 - 0.53 (0.47), 0.52 (0.50)

  • Counting fingers - 0.34 (0.36), 0.37 (0.00)

  • By level of VA:

  • No DR - 33%

  • 6/6-6/9 - 45%

  • 6/12-6/18 - 9%

  • 6/24-6/36 - 7%

  • 6/60-6/120 - 5%

  • Counting fingers - 2%

  • By level of VA:

  • No DR 75.0 (20.6)

  • 6/6-6/9 - 73.8 (18.1)

  • 6/12-6/18 - 57.7 (22.7)

  • 6/24-6/36 - 65.9 (21.1)

  • 6/60-6/120 - 52.3 (31.3)

  • Counting fingers -50.1 (9.0)
 Smith et al. 2008 (31) EQ-5D 0.8 (0.18) Median group >20/20
Conjunctivitis
 Pitt et al. 2004 (32) EQ-5D -

  • SAC 81.69 (14.89)

  • Control 84.92 (12.54)
 Rajagopalan et al. 2005 (33) EQ-5D

  • Control 0.87 (0.03)

  • Non-SS KCS 0.82 (0.02)

  • SS 0.74 (0.03)

  • Control 88.93 (2.06)

  • Non-SS KCS 82.45 (1.19)

  • SS 66.94 (2.43)
 Smith et al. 2005 (34) EQ-5D -

  • SAC 80.09 (15.24)

  • Control 83.34 (11.86)
Other visual disorders
 Boulton et al. 2006 (35) HUI-3 0.34 (0.43)
 Clark et al. 2008 (36) EQ-5D

  • Cases 0.66 (0.32)

  • Controls 0.81 (0.25)
 Kempen et al. 2003 (37) EQ-5D

  • No CMV = 0.71

  • Long standing CMV = 0.75

  • Newly diagnosed CMV = 0.75

  • No CMV = 91 (median)

  • Long standing CMV = 88

  • Newly diagnosed CMV = 88

  • No CMV = 72.5

  • Long standing CMV = 72.2

  • Newly diagnosed CMV = 63.9
 Langelaan et al. 2007 (38) EQ-5D 0.73 (0.22) Functional Acuity Score 38.61 (26.5)
 Quinn et al. 2007 (39) HUI-3

  • All subjects 0.59 (0.39)

  • Blind or low vision in better eye 0.25 (0.37)

  • Sighted in better eye 0.78 (0.25)

  • No-ROP subjects 0.90 (0.16)

  • All subjects - 20/63

  • Blind or low vision in better eye - Blind

  • Sighted in better eye - 20/40

  • No-ROP subjects - 20/20
 Van Nispen et al. 2009 (40) EQ-5D

  • Respondents 0.69 (0.24)

  • Nonrespondents 0.57 (0.29)

  • Respondents 0.55 [0.42;0.77]

  • Nonrespondents 0.52 [0.41;0.80]

CMV, cytomegalovirus retinitis; DR, diabetic retinopathy; non-SS KCS, non-SS or keratoconjunctivitis; PL, perception of light; ROP, retinopathy of prematurity; SAC, seasonal allergic conjunctivitus; SS, Sjogren's Syndrome.